|
Symposium
[Free Online Symposium] Oxbryta® (Voxelotor) tablets for Sickle Cell Disease: The R&D Journey and Lessons Learned (jointly by PBSS and CLSA)
Speakers:
Mira Pochron PhD (Head of Translational Biology, Global Blood Therapeutics)
Organizers:
Dennis Hu, Cyrus Khojasteh and Dewakar Sangaraju (all of Genentech)
Date:
2021-02-16
Time:
12:00-13:30 Pacific Time
Registration fee:
(USD):
Location:
Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2021-02-15
(it will close sooner if the seating cap is reached)
About the Topic
Building upon nearly 70 years of research in sickle cell disease (SCD) pathology, voxelotor, an HbS polymerization inhibitor, was developed to treat
the root cause of SCD pathophysiology. In 2019, the FDA granted Oxbryta® (Voxelotor) accelerated approval using hemoglobin, a biologic surrogate endpoint, indicative of reduced SCD hemolysis. In this presentation, we will share the R&D journey of Oxbryta®.
This presentation is part of the symposium series “Success Stories of Recently Approved Drugs and Lessons Learned”, jointly organized by PBSS and CLSA (California Life Science Association, a trade association representing California’s life science industry). About the SpeakersMira Pochron, PhD
Staff Scientist, Head of Translational Biology
Global Blood Therapeutics, Inc
Dr. Mira Pochron currently serves as the Head of Translational Biology at Global Blood Therapeutics (GBT). During her tenure at GBT she was an integral part of developing and overseeing the collection of pharmacodynamic data in the phase 1/2a studies with voxelotor and continues to oversee the collection of pharmacodynamic and biomarker data. She has been with GBT since it’s early days in 2011 and been a core team member involved in assay development, compound screening and animal studies with Hb modifiers, such as voxelotor. Dr. Pochron received her Ph.D. in Chemistry and Biochemistry from University of California, Santa Cruz.
2021-03-09, [Free Online Workshop] Metabolite Identification: Strategies, Techniques and Case Studies
|
2021-03-23, [Free Online Symposium] Cardiac Safety from Preclinical to the Clinic: Industry and Regulatory Trends in T-QT and Concentration-QT Studies for Assessing QT Prolongation Risks
|
2021-04-26, [Free Online Symposium] Highlights from 2020's FDA New Drug Approvals (jointly by PBSS and CLSA)
|
2021-07-29, [Free Online Symposium] Development of Inhalation Therapeutics (jointly by AAPS-BADG / PBSS / Genentech)
|
2021-09-23, [Free Online Symposium] Drug-Drug Interaction - Industry Trends and the 2020 FDA Guidances
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
|
Eurofins Selcia
14C Custom Radiolabelling for pre-clinical studies (ADME, drug metabolism, QWBA) and GMP 14C-API for hAME, clinical mass balance /micro-dosing.
|
Eurofins Discovery Biomarker Services
Cytokine Storm Assay for immunosafety profiles, STING Assay for in-depth evaluation of immune impacts; 360+ multiparameter flow cytometry capabilities
|
BioPharmEquip
Isolators, PCM-based Smart Temp-Controlled Packaging, Viable Air Sampler, -80C Biorepository Walk-Ins, Stability Chambers, Single-Use Containment
|
Hypha Discovery
Synthesis, purification & NMR characterization of drug metabolites at mg-g scale with COAs, including CYP/AOX/FMO metabolites, glucuronides & sulfates
|
Eurofins Discovery On-Demand
Take a coffee break with Discovery On-Demand! Mini webinars for remote learning avail 24/7 to accelerate your drug discovery program with confidence.
|
Submit a Text Ad
|